ORR increases to 82% with additional Partial Response in azer-cel CAR T Relapsed Ph 1b trial December 2, 2025
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours December 2, 2025
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients with R/R B-ALL December 2, 2025
European Commission (EC) grants approval to Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with R/R, BTK inhibitor-treated MCL December 2, 2025
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Biotherapeutics in Oncology December 2, 2025
Ph 3 Trial of Sac-TMT in Combination with KEYTRUDA as 1L Treatment for PD-L1-Positive NSCLC Met Primary Endpoint December 2, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with early gastric/GEJ cancers December 2, 2025
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics December 2, 2025
Vaximm signs non-binding term sheet with BCM Europe (BCME) for a potential exclusive worldwide licence for VXM01 December 2, 2025
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth December 2, 2025
Clinical results of glecirasib in combination with JAB-3312 (sitneprotafib) in KRAS G12C–mutated NSCLC published in The Lancet Respiratory Medicine December 2, 2025
The Annals of Oncology Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma December 2, 2025
Data from Acclaim-1 Ph 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer December 2, 2025
Update from ongoing TEM-GBM study in newly diagnosed GBM patients with an unmethylated gene promoter announced December 2, 2025
HREC provides human ethics approval for HARNESS-1 Ph 1a/b trial of RC220 in patients with EGFR-mutated NSCLC December 2, 2025
BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of R/R Multiple Myeloma Announced December 2, 2025
